Stereotaxis has announced that it has submitted its robotically navigated catheter, EMAGIN 5F, for FDA regulatory clearance $STXS
https://t.co/EjX1jF1GjH
Medicus Pharma announced that its SKNJCT-003 Phase 2 study, evaluating the efficacy of two dose levels of D-MNA for the treatment of nodular basal cell carcinoma (BCC), has now randomized more than 50% of the 60 patients targeted for enrollment $MDCX
https://t.co/OFkWgbU2EM
Biodexa Pharmaceuticals has announced that eRapa, a form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP), has been granted Fast Track Designation by the FDA $BDRX
https://t.co/ddz00fprU2
Esko Bionics names National Seating & Mobility as exclusive distributor of Ekso Indego Personal device within the complex rehabilitation technology industry $EKSO
https://t.co/Dk66lzNRxh
New data from BioRestorative Therapies’ ongoing Phase 2 trial of cell-based BRTX-100 in cLDD potentially show disc microenvironment remodeling in addition to reported improvements in VAS and ODI $BRTX
https://t.co/LWbeImf67H
In our latest #BioTuesdays feature, CEO Melissa Sherman, Ph.D., shares how @MobilionSystems, is redefining analytical characterization with next-gen separation science.
https://t.co/81nPBMgUkm
Tonix Pharmaceuticals has announced the appointment of Siobhan Fogarty as chief technical officer (CTO), effective immediately $TNXP
https://t.co/DnhLBeHYRh
Tectonic Therapeutic has announced positive interim data from its Phase 1b acute hemodynamic clinical trial of TX45 in Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) $TECX
https://t.co/cmx80bI1bI
Polyrizon has announced the filing of a patent application for its advanced intranasal drug delivery system Trap & Target (T&T) technology, with the Israel Patent Office (ILPO) $PLRZ
https://t.co/dkOIeGMLAq
NLS Pharmaceutics has announced the launch of a preclinical program to evaluate Mazindol ER as a novel treatment for fentanyl dependence $NLSP
https://t.co/FMYfjTSN2a
Conduit Pharmaceuticals has announced that the first phase in its collaboration with Sarborg, aimed at integrating advanced AI and cybernetics technology into its operations has been completed $CDT
https://t.co/TwoQISEzLL
Stereotaxis has announced that it has received European CE Mark approval for its MAGIC ablation catheter, designed to perform cardiac ablation procedures aimed at treating heart arrhythmia $STXS
https://t.co/b0zezUvy1f
Veru has announced positive topline results from its Phase 2b QUALITY clinical study evaluating the safety and efficacy of enobosarm in patients receiving WEGOVY (semaglutide) for weight reduction $VERU
https://t.co/W7OHL9sagj
IPA (ImmunoPrecise Antibodies) has announced the development of a new class of GLP-1 therapies—leveraging AI—to enhance the efficacy, safety, and longevity of treatments for Type 2 diabetes (T2D) and obesity $IPA
https://t.co/10h1kZcseA
MeiraGTx has announced that its AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations (LCA1) has been granted Rare Pediatric Disease Designation (RPDD) by the FDA $MGTX
https://t.co/gXUygUTrsM